Myomo (MYO)
(Delayed Data from AMEX)
$3.39 USD
-0.12 (-3.42%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $3.39 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Brokerage Reports
Myomo, Inc. [MYO]
Reports for Purchase
Showing records 1 - 20 ( 118 total )
Company: Myomo, Inc.
Industry: Medical - Products
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
We are updating our Healthcare coverage to reflect a recent analyst departure and to drop
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Entering High Growth Period Following CMS Reimbursement Approval; Initiating With Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
1Q:23 Revenue In Line With Expectations; We Narrow Our Loss Estimates For 2023 And 2024
Provider: Sidoti CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Forecast Narrower Losses In 2023-2024 Due To Cost Cuts And Improving Reimbursement
Provider: Sidoti CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
4Q:22 Revenue In Line With Expectation,Maintain $6 Price Target
Provider: Sidoti CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Raises $6 Million Through An Equity Offering; Adjust Loss-Per-Share Estimates For 2023-2024
Provider: Sidoti CSR
Analyst: Research Department
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Company: Myomo, Inc.
Industry: Medical - Products
Lower 2023 Estimate To Reflect Higher Advertising, Materials Costs; Reduce Price Target To $16
Provider: Sidoti CSR
Analyst: Research Department